REFERENCES
1. Chan KE, Koh TJL, Tang ASP, et al. Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: a meta-analysis and systematic review of 10 739 607 individuals. J Clin Endocrinol Metab. 2022;107:2691-700.
2. Eslam M, El-Serag HB, Francque S, et al. Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nat Rev Gastroenterol Hepatol. 2022;19:638-51.
3. Eslam M, Fan JG, Yu ML, et al. The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease. Hepatol Int. 2025.
4. Eslam M, Ahmed A, Després JP, et al. Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases. Lancet Gastroenterol Hepatol. 2021;6:743-53.
5. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-8.
7. Eslam M, Fan JG, Mendez-Sanchez N. Non-alcoholic fatty liver disease in non-obese individuals: the impact of metabolic health. Lancet Gastroenterol Hepatol. 2020;5:713-5.
8. Byrne CD, Targher G. MASLD, MAFLD, or NAFLD criteria: have we re-created the confusion and acrimony surrounding metabolic syndrome?. Metab Target Organ Damage. 2024;4:10.
10. Eslam M, Alkhouri N, Vajro P, et al. Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement. Lancet Gastroenterol Hepatol. 2021;6:864-73.
11. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202-9.
12. Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158:1999-2014.e1.
13. Eslam M, Sarin SK, Wong VW, et al. The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889-919.
14. Fouad Y, Sanai F, Alboraie M, Zheng MH. What the new definition of MASLD left behind: dual etiology with viral hepatitis. Clin Gastroenterol Hepatol. 2024;22:1751-2.
15. Méndez-Sánchez N, Bugianesi E, Gish RG, et al; Global multi-stakeholder consensus on the redefinition of fatty liver disease. Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol. 2022;7:388-90.
16. Alharthi J, Gastaldelli A, Cua IH, Ghazinian H, Eslam M. Metabolic dysfunction-associated fatty liver disease: a year in review. Curr Opin Gastroenterol. 2022;38:251-60.
17. Alboraie M, Tanwandee T, Xu X, et al. Global multi-societies endorsement of the MAFLD definition. Ann Hepatol. 2024;29:101573.
18. Rinella ME, Lazarus JV, Ratziu V, et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542-56.
19. Fan JG, Xu XY, Yang RX, et al; Chinese Society of Hepatology, Chinese Medical Association. Guideline for the prevention and treatment of metabolic dysfunction-associated fatty liver disease (version 2024). J Clin Transl Hepatol. 2024;12:955-74.
20. Rinella ME, Lazarus JV, Ratziu V, et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966-86.
21. Díaz LA, Arab JP, Louvet A, Bataller R, Arrese M. The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2023;20:764-83.
22. Tourkochristou E, Assimakopoulos SF, Thomopoulos K, Marangos M, Triantos C. NAFLD and HBV interplay - related mechanisms underlying liver disease progression. Front Immunol. 2022;13:965548.
23. Zheng Q, Zou B, Wu Y, et al. Systematic review with meta-analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B. Aliment Pharmacol Ther. 2021;54:1100-9.
24. Zhang M, Chen S, Wu X, et al. Persistent steatosis correlates with decreased fibrosis regression during anti-HBV treatment in patients with chronic HBV infection. J Med Virol. 2023;95:e29156.
25. Patmore LA, Katwaroe WK, van der Spek D, et al. Association between the presence of metabolic comorbidities and liver-related events in patients with chronic hepatitis B. Clin Gastroenterol Hepatol. 2023;21:3089-96.e1.
26. Lin S, Wang M, Liu Y, et al. Concurrence of HBV infection and non-alcoholic fatty liver disease is associated with higher prevalence of chronic kidney disease. Clin Res Hepatol Gastroenterol. 2021;45:101483.
27. Attia D, Abdel Alem S, El-Akel W, et al. Prevalence and clinical characteristics of patients with metabolic dysfunction-associated fatty liver disease with hepatitis C virus infection-a population-based study. Aliment Pharmacol Ther. 2022;56:1581-90.
28. Cheng KL, Wang SW, Cheng YM, Hsieh TH, Wang CC, Kao JH. Prevalence and clinical outcomes in subtypes of metabolic associated fatty liver disease. J Formos Med Assoc. 2024;123:36-44.
29. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology. 2004;126:586-97.
30. Huang CF, Dai CY, Yeh ML, et al. Association of diabetes and PNPLA3 genetic variants with disease severity of patients with chronic hepatitis C virus infection. J Hepatol. 2015;62:512-8.
31. Younossi ZM, McCullough AJ, Ong JP, et al. Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol. 2004;38:705-9.
32. Khattab MA, Eslam M, Mousa YI, et al. Association between metabolic abnormalities and hepatitis C-related hepatocellular carcinoma. Ann Hepatol. 2012;11:487-94.
33. Eslam M, Kawaguchi T, Del Campo JA, Sata M, Khattab MA, Romero-Gomez M. Use of HOMA-IR in hepatitis C. J Viral Hepat. 2011;18:675-84.
34. Lonardo A, Adinolfi LE, Restivo L, et al. Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen. World J Gastroenterol. 2014;20:7089-103.
35. Wong RJ, Chou C, Sinha SR, Kamal A, Ahmed A. Ethnic disparities in the association of body mass index with the risk of hypertension and diabetes. J Community Health. 2014;39:437-45.
36. Shih CI, Wu KT, Hsieh MH, et al. Severity of fatty liver is highly correlated with the risk of hypertension and diabetes: a cross-sectional and longitudinal cohort study. Hepatol Int. 2024;18:138-54.
37. Yu ML, Chuang WL. Path from the discovery to the elimination of hepatitis C virus: honoring the winners of the Nobel prize in physiology or medicine 2020. Kaohsiung J Med Sci. 2021;37:7-11.
38. Liu CJ, Seto WK, Yu ML. Dual-etiology MAFLD: the interactions between viral hepatitis B, viral hepatitis C, alcohol, and MAFLD. Hepatol Int. 2024;18:897-908.
39. Carvalho AF, Heilig M, Perez A, Probst C, Rehm J. Alcohol use disorders. Lancet. 2019;394:781-92.
40. Åberg F, Puukka P, Salomaa V, et al. Combined effects of alcohol and metabolic disorders in patients with chronic liver disease. Clin Gastroenterol Hepatol. 2020;18:995-7.e2.
41. Chang Y, Cho YK, Kim Y, et al. Nonheavy drinking and worsening of noninvasive fibrosis markers in nonalcoholic fatty liver disease: a cohort study. Hepatology. 2019;69:64-75.
42. Tian C, Stokowski RP, Kershenobich D, Ballinger DG, Hinds DA. Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet. 2010;42:21-3.
43. Petrie E, Gray M, Bril F. Metabolic characteristics of patients with MetALD: caveats of a new definition. Liver Int. 2024;44:2929-38.
44. Alboraie M, Butt AS, Piscoya A, et al. Why MASLD lags behind MAFLD: a critical analysis of diagnostic criteria evolution in metabolic dysfunction-associated liver diseases. Med Sci Monit. 2024;30:e945198.
45. Holbeck M, DeVries HS, Singal AK. Integrated multidisciplinary management of alcohol-associated liver disease. J Clin Transl Hepatol. 2023;11:1404-12.
46. Musto JA, Brown R, Lucey MR. Is there a safe limit for consumption of alcohol?. J Hepatol. 2025;82:535-40.
47. Meijnikman AS, Nieuwdorp M, Schnabl B. Endogenous ethanol production in health and disease. Nat Rev Gastroenterol Hepatol. 2024;21:556-71.
48. Boniface S, Kneale J, Shelton N. Drinking pattern is more strongly associated with under-reporting of alcohol consumption than socio-demographic factors: evidence from a mixed-methods study. BMC Public Health. 2014;14:1297.
49. Joo EJ, Chang Y, Yeom JS, Ryu S. Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: a cohort study. Hepatology. 2017;65:828-35.
50. Seto WK. Chronic hepatitis B and metabolic risk factors: a call for rigorous longitudinal studies. World J Gastroenterol. 2019;25:282-6.
51. Wong VW, Wong GL, Chu WC, et al. Hepatitis B virus infection and fatty liver in the general population. J Hepatol. 2012;56:533-40.
52. Sarin SK, Kumar M, Eslam M, et al. Liver diseases in the Asia-Pacific region: a lancet gastroenterology & hepatology commission. Lancet Gastroenterol Hepatol. 2020;5:167-228.
53. Huang JF, Dai CY, Hwang SJ, et al. Hepatitis C viremia increases the association with type 2 diabetes mellitus in a hepatitis B and C endemic area: an epidemiological link with virological implication. Am J Gastroenterol. 2007;102:1237-43.
54. van Kleef LA, Choi HSJ, Brouwer WP, et al. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B. JHEP Rep. 2021;3:100350.
55. Manzano-Nunez R, Rivera-Esteban J, Navarro J, et al. Uncovering the NAFLD burden in people living with HIV from high- and middle-income nations: a meta-analysis with a data gap from Subsaharan Africa. J Int AIDS Soc. 2023;26:e26072.
56. Díaz LA, Ayares G, Arnold J, et al. Liver diseases in latin america: current status, unmet needs, and opportunities for improvement. Curr Treat Options Gastroenterol. 2022;20:261-78.
57. Müller L. Integrated approaches in chronic disease management: a new model for internal medicine. Arch Med. 2025;17:001-2. Available from: https://www.itmedicalteam.pl/articles/integrated-approaches-in-chronic-disease-management-a-new-model-for-internal-medicine.pdf [Last accessed on 27 Mar 2025].
58. Okpujie V, Tobalesi O, Uwumiro F, et al. The influence of insulin resistance on outcomes in hospitalizations for alcohol-related liver disease: a nationwide study. Cureus. 2023;15:e42964.
59. Kernick D, Chew-Graham CA, O’Flynn N. Clinical assessment and management of multimorbidity: NICE guideline. Br J Gen Pract. 2017;67:235-6.
60. Fernandez CJ, Alkhalifah M, Afsar H, Pappachan JM. Metabolic dysfunction-associated fatty liver disease and chronic viral hepatitis: the interlink. Pathogens. 2024;13:68.
61. Zhang H, Targher G, Byrne CD, et al; MAFLD ICD-11 coding collaborators. A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease. Hepatol Int. 2024;18:1178-201.
62. Zhou XD, Lonardo A, Pan CQ, Shapiro MD, Zheng MH; WMU MAFLD Clinical Research Working Group. Clinical features and long-term outcomes of patients diagnosed with MASLD, MAFLD, or both. J Hepatol. 2024;81:e157-9.
63. Åberg F, Byrne CD, Pirola CJ, Männistö V, Sookoian S. Alcohol consumption and metabolic syndrome: clinical and epidemiological impact on liver disease. J Hepatol. 2023;78:191-206.
64. Pan Z, Khatry MA, Yu ML, et al. MAFLD: an ideal framework for understanding disease phenotype in individuals of normal weight. Ther Adv Endocrinol Metab. 2024;15:20420188241252543.
65. Pan Z, Al-Busafi SA, Abdulla M, Fouad Y, Sebastiani G, Eslam M. MAFLD identifies patients with significant hepatic fibrosis better than MASLD. Hepatol Int. 2024;18:964-72.
66. Pan Z, Eslam M; panel of collaborators. The MASLD criteria overlook a number of adolescent patients with severe steatosis. J Hepatol. 2024;81:e80-1.
67. Pan Z, Shiha G, Esmat G, Méndez-Sánchez N, Eslam M. MAFLD predicts cardiovascular disease risk better than MASLD. Liver Int. 2024;44:1567-74.
68. Pan Z, Derbala M, AlNaamani K, Ghazinian H, Fan JG, Eslam M. MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney disease. Ann Hepatol. 2024;29:101512.
69. Hoang T, Lee J, Kim BH, Cho Y, Kim J. Evaluation of nomenclature of fatty liver disease in association with hepatocellular carcinoma: a 14.5-year cohort study in Korea. Cancer Res Treat. 2025;Epub ahead of print.
70. Vaz K, Kemp W, Majeed A, et al. MAFLD but not MASLD increases risk of all-cause mortality in regional Australia, with components of metabolic syndrome exacerbating factors: 20 year longitudinal, cohort study. Hepatol Int. 2024;Epub ahead of print.
71. Jiang M, Pan Z, George J, Eslam M. Clinical features and mortality outcomes of patients with MASLD only compared to those with MAFLD and MASLD. Hepatol Int. 2024;18:1731-9.
72. Pan Z, Yilmaz Y, Al-Busafi SA, Eslam M. The MAFLD definition identifies three homogenous groups of patients. Liver Int. 2024;44:3287-9.
73. Zhao Q, Deng Y. Comparison of mortality outcomes in individuals with MASLD and/or MAFLD. J Hepatol. 2024;80:e62-4.
